[
  {
    "text": "1.21.",
    "bbox": [
      144,
      71,
      181,
      85
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "Regulatory Authorities shall mean the FDA, each Competent Authority, Health Canada and the Japanese Pharmaceuticals and",
    "bbox": [
      214,
      73,
      1000,
      84
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "Medical Devices Agency.",
    "bbox": [
      213,
      88,
      405,
      101
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "1.22.",
    "bbox": [
      144,
      103,
      181,
      117
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "Revenue Affiliate shall mean any entity of which Sekisui has the direct or indirect power to vote more than fifty percent (50%) of the",
    "bbox": [
      213,
      104,
      1000,
      117
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "direct or indirect ability to direct or cause the direction of the general management and policies of that entity.",
    "bbox": [
      213,
      136,
      1000,
      149
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "1.23.",
    "bbox": [
      144,
      152,
      181,
      165
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "Sale Transaction shall mean (i) any transaction in which Qualigen, Qualigen's business or control of Qualigen is acquired, (ii) any",
    "bbox": [
      212,
      152,
      1000,
      166
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "license, sale, lease, transfer, or other disposition, in a single transaction or series of related transactions, of all or substantially all of",
    "bbox": [
      212,
      168,
      1000,
      181
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "Qualigen's assets other than in the ordinary course of business, (iii) any sale of a majority of the outstanding shares of capital stock",
    "bbox": [
      214,
      185,
      1000,
      197
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "of Qualigen, (iv) any sale or license of any rights to any Qualigen products, now or hereafter existing, other than in the ordinary",
    "bbox": [
      214,
      201,
      1000,
      213
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "course of business, (v) any liquidation or dissolution of Qualigen, (vi) any similar transaction resulting in a change of control of",
    "bbox": [
      214,
      217,
      1000,
      229
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "Qualigen, or (vii) any of the foregoing with respect to any now or hereafter existing subsidiary of Qualigen which holds, on a",
    "bbox": [
      214,
      233,
      1000,
      245
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "consolidated basis, all or substantially all of Qualigen's assets (i.e., of the assets of Qualigen and all its Affiliates considered",
    "bbox": [
      213,
      249,
      1000,
      261
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "together).",
    "bbox": [
      211,
      264,
      287,
      278
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "1.24.",
    "bbox": [
      144,
      279,
      181,
      293
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "Serious Incident shall mean an incident involving the Products, which is reportable to a Competent Authority and as defined in",
    "bbox": [
      214,
      282,
      1000,
      292
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "Section 5 of Annex III of the IVD Directive, and the European Commission Medical Devices Vigilance Guidelines 2.12-1 or such other",
    "bbox": [
      213,
      297,
      1000,
      309
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "Guidelines as may be issued from time to time.",
    "bbox": [
      214,
      314,
      557,
      324
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "1.25.",
    "bbox": [
      144,
      327,
      180,
      341
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "Territory shall mean worldwide excluding Qualigen Retained Customers.",
    "bbox": [
      213,
      329,
      751,
      341
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "1.26.",
    "bbox": [
      144,
      344,
      181,
      357
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "Third Party shall mean a party other than Sekisui or Qualigen or any Affiliate of Sekisui or Qualigen.",
    "bbox": [
      212,
      344,
      960,
      357
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "2.",
    "bbox": [
      109,
      360,
      127,
      372
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "Appointment and Term",
    "bbox": [
      181,
      361,
      353,
      372
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "2.1.",
    "bbox": [
      144,
      376,
      173,
      388
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "Appointment. Qualigen hereby appoints Sekisui, and Sekisui accepts the appointment to act on an exclusive basis pursuant to the",
    "bbox": [
      214,
      377,
      1000,
      389
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "terms and conditions of this Agreement, as a distributor for the sale of the Products in the Territory. Sekisui shall be permitted to",
    "bbox": [
      213,
      392,
      1000,
      404
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "appoint sub-distributors in the Territory (including any current Qualigen distributors) with the approval of Qualigen, not to be",
    "bbox": [
      212,
      408,
      1000,
      421
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "unreasonably withheld or delayed. Sekisui shall purchase the Products exclusively from Qualigen, and Qualigen shall supply the",
    "bbox": [
      213,
      425,
      1000,
      437
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "Products exclusively to Sekisui, in each case for the Territory. Qualigen shall assign to Sekisui Qualigen's agreements with Qualigen's",
    "bbox": [
      212,
      440,
      1000,
      453
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "current distributors (such that such current Qualigen distributors shall become Sekisui subdistributors), each of which is set forth on",
    "bbox": [
      212,
      457,
      1000,
      469
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "Schedule 2.1 hereto; if any of such agreements do not allow such assignment and the current distributor declines to consent to such",
    "bbox": [
      214,
      473,
      1000,
      485
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "an assignment to Sekisui, Qualigen shall (if Sekisui so requests) act pursuant to such agreement to terminate such agreement.",
    "bbox": [
      212,
      489,
      1000,
      501
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "2.2.",
    "bbox": [
      143,
      503,
      173,
      517
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "Term. The initial term of this Agreement shall commence on the Effective Date and shall continue for a period of five (5) years unless",
    "bbox": [
      213,
      505,
      1000,
      517
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "earlier terminated pursuant to Section 14 hereof (the \"Term'). The initial term of this Agreement and any renewal term thereof shall be",
    "bbox": [
      213,
      521,
      1000,
      533
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "automatically extended at the end of the initial term and any renewal term thereof for an additional one (1) year period unless either",
    "bbox": [
      213,
      537,
      1000,
      549
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "Party notifies the other Party not less than six (6) months before the end of the then in effect term of its intent to terminate this",
    "bbox": [
      214,
      553,
      1000,
      563
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "Agreement. References in this Agreement to \"Term\"' shall be deemed to include the initial five (5) year term as well as a reduction or",
    "bbox": [
      214,
      569,
      1000,
      581
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "extension of that time period that may occur as a result of the provision of this Section 0 or the provisions of Section 14.",
    "bbox": [
      214,
      585,
      1000,
      597
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "3",
    "bbox": [
      660,
      601,
      672,
      611
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "Source: RITTER PHARMACEUTICALS INC, S-4/A, 3/13/2020",
    "bbox": [
      133,
      1000,
      606,
      1000
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "1.21.",
    "bbox": [
      144,
      71,
      181,
      85
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "Regulatory Authorities shall mean the FDA, each Competent Authority, Health Canada and the Japanese Pharmaceuticals and",
    "bbox": [
      214,
      73,
      1000,
      84
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "Medical Devices Agency.",
    "bbox": [
      213,
      88,
      405,
      101
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "1.22.",
    "bbox": [
      144,
      103,
      181,
      117
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "Revenue Affiliate shall mean any entity of which Sekisui has the direct or indirect power to vote more than fifty percent (50%) of the",
    "bbox": [
      213,
      104,
      1000,
      117
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "direct or indirect ability to direct or cause the direction of the general management and policies of that entity.",
    "bbox": [
      213,
      136,
      1000,
      149
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "1.23.",
    "bbox": [
      144,
      152,
      181,
      165
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "Sale Transaction shall mean (i) any transaction in which Qualigen, Qualigen's business or control of Qualigen is acquired, (ii) any",
    "bbox": [
      212,
      152,
      1000,
      166
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "license, sale, lease, transfer, or other disposition, in a single transaction or series of related transactions, of all or substantially all of",
    "bbox": [
      212,
      168,
      1000,
      181
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "Qualigen's assets other than in the ordinary course of business, (iii) any sale of a majority of the outstanding shares of capital stock",
    "bbox": [
      214,
      185,
      1000,
      197
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "of Qualigen, (iv) any sale or license of any rights to any Qualigen products, now or hereafter existing, other than in the ordinary",
    "bbox": [
      214,
      201,
      1000,
      213
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "course of business, (v) any liquidation or dissolution of Qualigen, (vi) any similar transaction resulting in a change of control of",
    "bbox": [
      214,
      217,
      1000,
      229
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "Qualigen, or (vii) any of the foregoing with respect to any now or hereafter existing subsidiary of Qualigen which holds, on a",
    "bbox": [
      214,
      233,
      1000,
      245
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "consolidated basis, all or substantially all of Qualigen's assets (i.e., of the assets of Qualigen and all its Affiliates considered",
    "bbox": [
      213,
      249,
      1000,
      261
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "together).",
    "bbox": [
      211,
      264,
      287,
      278
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "1.24.",
    "bbox": [
      144,
      279,
      181,
      293
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "Serious Incident shall mean an incident involving the Products, which is reportable to a Competent Authority and as defined in",
    "bbox": [
      214,
      282,
      1000,
      292
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "Section 5 of Annex III of the IVD Directive, and the European Commission Medical Devices Vigilance Guidelines 2.12-1 or such other",
    "bbox": [
      213,
      297,
      1000,
      309
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "Guidelines as may be issued from time to time.",
    "bbox": [
      214,
      314,
      557,
      324
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "1.25.",
    "bbox": [
      144,
      327,
      180,
      341
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "Territory shall mean worldwide excluding Qualigen Retained Customers.",
    "bbox": [
      213,
      329,
      751,
      341
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "1.26.",
    "bbox": [
      144,
      344,
      181,
      357
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "Third Party shall mean a party other than Sekisui or Qualigen or any Affiliate of Sekisui or Qualigen.",
    "bbox": [
      212,
      344,
      960,
      357
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "2.",
    "bbox": [
      109,
      360,
      127,
      372
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "Appointment and Term",
    "bbox": [
      181,
      361,
      353,
      372
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "2.1.",
    "bbox": [
      144,
      376,
      173,
      388
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "Appointment. Qualigen hereby appoints Sekisui, and Sekisui accepts the appointment to act on an exclusive basis pursuant to the",
    "bbox": [
      214,
      377,
      1000,
      389
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "terms and conditions of this Agreement, as a distributor for the sale of the Products in the Territory. Sekisui shall be permitted to",
    "bbox": [
      213,
      392,
      1000,
      404
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "appoint sub-distributors in the Territory (including any current Qualigen distributors) with the approval of Qualigen, not to be",
    "bbox": [
      212,
      408,
      1000,
      421
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "unreasonably withheld or delayed. Sekisui shall purchase the Products exclusively from Qualigen, and Qualigen shall supply the",
    "bbox": [
      213,
      425,
      1000,
      437
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "Products exclusively to Sekisui, in each case for the Territory. Qualigen shall assign to Sekisui Qualigen's agreements with Qualigen's",
    "bbox": [
      212,
      440,
      1000,
      453
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "current distributors (such that such current Qualigen distributors shall become Sekisui subdistributors), each of which is set forth on",
    "bbox": [
      212,
      457,
      1000,
      469
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "Schedule 2.1 hereto; if any of such agreements do not allow such assignment and the current distributor declines to consent to such",
    "bbox": [
      214,
      473,
      1000,
      485
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "an assignment to Sekisui, Qualigen shall (if Sekisui so requests) act pursuant to such agreement to terminate such agreement.",
    "bbox": [
      212,
      489,
      1000,
      501
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "2.2.",
    "bbox": [
      143,
      503,
      173,
      517
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "Term. The initial term of this Agreement shall commence on the Effective Date and shall continue for a period of five (5) years unless",
    "bbox": [
      213,
      505,
      1000,
      517
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "earlier terminated pursuant to Section 14 hereof (the \"Term'). The initial term of this Agreement and any renewal term thereof shall be",
    "bbox": [
      213,
      521,
      1000,
      533
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "automatically extended at the end of the initial term and any renewal term thereof for an additional one (1) year period unless either",
    "bbox": [
      213,
      537,
      1000,
      549
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "Party notifies the other Party not less than six (6) months before the end of the then in effect term of its intent to terminate this",
    "bbox": [
      214,
      553,
      1000,
      563
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "Agreement. References in this Agreement to \"Term\"' shall be deemed to include the initial five (5) year term as well as a reduction or",
    "bbox": [
      214,
      569,
      1000,
      581
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "extension of that time period that may occur as a result of the provision of this Section 0 or the provisions of Section 14.",
    "bbox": [
      214,
      585,
      1000,
      597
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "3",
    "bbox": [
      660,
      601,
      672,
      611
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "Source: RITTER PHARMACEUTICALS INC, S-4/A, 3/13/2020",
    "bbox": [
      133,
      1000,
      606,
      1000
    ],
    "label": 33,
    "category": "Audit Rights"
  }
]